Abstract
BACKGROUND/AIMS: Recently, 1-L polyethylene glycol-ascorbic acid (PEG-Asc) has been used to reduce the volume of preparation agents in colonoscopy. This clinical trial aimed to compare the efficacy and safety of two types of 1-L PEG-Asc (CleanViewAL(®) [Tae Joon Pharmaceutical Company, Seoul, Korea] and Plenvu(®) [Norgine, Harefield, United Kingdom]) in average-aged adults. METHODS: This study was a prospective, randomized, non-inferiority, open-label, phase 4 clinical trial. The primary endpoint was the efficacy evaluated using the Boston bowel preparation scale (BBPS), and the secondary endpoint was clinical safety. RESULTS: In total, 173 patients were assigned to either the CleanViewAL(®) (n=84) or Plenvu(®) (n=89) group. Overall cleansing successes of 97.6% (82/84) and 98.8% (88/89) were achieved in the CleanViewAL(®) group and in the Plenvu(®) group, respectively, showing that CleanViewAL(®) has similar bowel cleansing efficacy to Plenvu(®) (95% CI, -0.052 to 0.027; p=0.207). The total BBPS score was 8.67±1.00 and 8.70±0.76 in the CleanViewAL(®) group and Plenvu(®) group, respectively (p=0.869). The most common adverse symptom was nausea, and no adverse symptoms requiring hospitalization were reported in either group. There were no cases of critical hypernatremia and liver dysfunction exceeding the common terminology criteria for adverse events grade I. An overall satisfaction score (scale of 1 to 10) showed no difference between the two groups (p=0.289). However, the CleanViewAL(®) group showed a higher taste satisfaction score (scale of 1 to 5) than the Plenvu(®) group (CleanViewAL(®): 2.90±0.91, Plenvu(®): 2.60±0.86, p=0.028). CONCLUSIONS: Both types of 1-L PEG-Asc, CleanViewAL(®) and Plenvu(®), are effective and safe bowel cleansing agents in average-aged adults. CleanViewAL(®) was preferred in terms of taste satisfaction.